HIGHLIGHTS
- who: Xiangting Jin from the Fudan University, China have published the Article: Durable effect of pyrotinib plus capecitabine in HER-2+ breast cancer patient undergoing peritoneal dialysis: A case report and literature review, in the Journal: (JOURNAL) of August/11,/2021
SUMMARY
In recent years, the incidence rate of end-stage renal disease (ESRD) patients has increased year by year. Renal replacement therapy such as peritoneal dialysis (PD) and hemodialysis (HD) can significantly prolong the survival time of ESRD patients. For the treatment of ESRD tumor patients, in July 2017, the Italian Association . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.